Coronary CT Angiogram: Which Tests to Order Alongside

What a Coronary CT Angiogram Actually Shows

A CCTA uses ECG-gated, contrast-enhanced computed tomography to generate three-dimensional images of the coronary arteries. It identifies luminal stenosis, non-calcified ("soft") plaque, mixed plaque, and calcified plaque with a sensitivity between 95% and 99% for detecting hemodynamically significant narrowing [1]. The 2022 AHA/ACC Chest Pain Guidelines now recommend CCTA as a first-line test for stable chest pain in patients with intermediate pretest probability [2].

But anatomy alone does not explain why plaque formed. Two patients with identical 50% stenosis can carry wildly different risk profiles depending on their LDL-C, inflammatory burden, insulin resistance, and genetic lipoprotein(a) levels. A CCTA without paired labs is like reading a topographic map with no weather data. You see the terrain. You miss the storm building behind it.

The 2019 ESC/EAS Dyslipidemia Guidelines recommend that imaging-confirmed atherosclerosis should trigger immediate reclassification into high or very-high cardiovascular risk categories, with corresponding LDL-C targets of <70 mg/dL or <55 mg/dL [3]. That reclassification depends on lab data you must already have in hand.

Coronary Artery Calcium Score: The Natural Companion

Order a CAC score either before or concurrently with the CCTA. It takes seconds to acquire, requires no contrast, and adds minimal radiation (typically 1 mSv). The CAC score quantifies calcified plaque burden on the Agatston scale. A score of zero carries a 10-year major adverse cardiac event (MACE) rate below 1%, while a score above 400 is associated with a 10-year event rate exceeding 20% [4].

The MESA study (N=6,814) demonstrated that CAC scoring reclassified 23% of intermediate-risk adults into either low-risk or high-risk categories, a shift that directly changed statin prescribing decisions [5]. The 2019 ACC/AHA Primary Prevention Guidelines give CAC scoring a Class IIa recommendation for adults aged 40 to 75 with borderline or intermediate 10-year ASCVD risk (5-20%) [6].

Why does this matter if the CCTA already shows plaque? Because CAC provides a single number that tracks over time. Serial CAC scoring (every 3 to 5 years) lets clinicians monitor whether therapies are halting plaque progression. The CCTA provides qualitative detail. The CAC score provides quantitative trajectory.

The Core Lipid Panel: Non-Negotiable Baseline Labs

Every CCTA should be paired with a fasting or non-fasting standard lipid panel: total cholesterol, LDL-C, HDL-C, and triglycerides. If triglycerides exceed 400 mg/dL, direct LDL-C measurement replaces the Friedewald calculation. The 2018 AHA/ACC Cholesterol Guidelines set an LDL-C target of <70 mg/dL for patients with confirmed atherosclerotic cardiovascular disease (ASCVD) and recommend considering <55 mg/dL for very-high-risk patients [7].

An advanced lipid panel adds apolipoprotein B (apoB) and LDL particle number (LDL-P). ApoB may be more predictive of cardiovascular events than LDL-C alone, particularly in patients with metabolic syndrome or diabetes where LDL-C can appear normal while particle number remains elevated [8]. The 2019 ESC/EAS Guidelines endorse apoB as a secondary treatment target (<65 mg/dL for very-high-risk patients) [3].

For patients whose CCTA reveals non-calcified plaque, discordance between LDL-C and apoB becomes especially relevant. A patient with an LDL-C of 95 mg/dL but an apoB of 110 mg/dL carries residual risk that standard lipid reporting would miss.

Lipoprotein(a): The One-Time Test That Changes Everything

Lipoprotein(a), or Lp(a), is a genetically determined, LDL-like particle that promotes both atherosclerosis and thrombosis. Approximately 20% of the global population carries Lp(a) levels above 50 mg/dL (or 125 nmol/L), the threshold associated with significantly increased cardiovascular risk [9]. The 2019 ESC/EAS Guidelines recommend measuring Lp(a) at least once in every adult's lifetime to identify those with very high inherited levels (above 180 mg/dL or 430 nmol/L) who carry a lifetime ASCVD risk equivalent to heterozygous familial hypercholesterolemia [3].

Lp(a) does not respond to statins. It barely moves with lifestyle changes. This makes it a fixed variable. If a patient's CCTA shows plaque and their Lp(a) is 85 mg/dL, the clinical conversation shifts: more aggressive LDL-C lowering, potential PCSK9 inhibitor initiation, and enrollment consideration for emerging Lp(a)-lowering therapies such as pelacarsen (currently in the phase 3 Lp(a)HORIZON trial, N=8,323) [10].

Dr. Vijay Nambi, associate professor of cardiology at Baylor College of Medicine, has stated: "If you find plaque on CCTA and you haven't checked Lp(a), you're missing a potentially dominant driver of that patient's disease. It's the single most under-ordered cardiovascular lab in clinical practice."

High-Sensitivity C-Reactive Protein: Measuring the Fire Behind the Plaque

High-sensitivity CRP (hs-CRP) quantifies systemic inflammation. The JUPITER trial (N=17,802) demonstrated that patients with LDL-C <130 mg/dL but hs-CRP ≥2.0 mg/L who received rosuvastatin experienced a 44% reduction in major cardiovascular events compared to placebo [11]. This finding established that inflammatory risk operates independently of cholesterol levels.

For a patient whose CCTA reveals mixed or non-calcified plaque, an hs-CRP above 2.0 mg/L signals active inflammatory atherosclerosis. The CANTOS trial (N=10,061) later proved the concept by showing that canakinumab (an IL-1β inhibitor) reduced cardiovascular events by 15% in patients with prior MI and hs-CRP ≥2.0 mg/L, independent of lipid lowering [12].

Pair hs-CRP with the CCTA result. A high plaque burden plus high hs-CRP places the patient in a very-high-risk category. A high plaque burden with low hs-CRP suggests a more stable, less inflammatory phenotype.

Glycemic Markers: HbA1c and Fasting Glucose

Type 2 diabetes doubles cardiovascular mortality risk. The ADA Standards of Care (2024) recommend HbA1c screening for all adults aged 35 and older, or younger adults with BMI ≥25 kg/m² and one additional risk factor [13]. When a CCTA is ordered, HbA1c and fasting glucose should appear on the same requisition.

An HbA1c between 5.7% and 6.4% indicates prediabetes. A value of 6.5% or higher confirms diabetes. For patients with confirmed coronary plaque on CCTA, identifying prediabetes is actionable: the Diabetes Prevention Program (N=3,234) showed that intensive lifestyle intervention reduced progression to diabetes by 58% over 2.8 years [14].

Fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance) can add further resolution. A patient with a normal HbA1c of 5.5% but a fasting insulin of 22 μIU/mL and HOMA-IR of 4.8 already has significant insulin resistance. That metabolic context shapes how aggressively you treat the plaque the CCTA found.

Renal Function: The Pre-Contrast Requirement

CCTA requires iodinated contrast. Before administering it, obtain serum creatinine and calculate eGFR. The American College of Radiology recommends caution when eGFR falls below 30 mL/min/1.73 m², and suggests pre-hydration protocols for eGFR between 30 and 44 mL/min/1.73 m² [15].

Beyond contrast safety, renal function itself is a cardiovascular risk modifier. The ARIC study (N=15,792) showed that each 15 mL/min decline in eGFR below 60 was associated with a 30% increase in coronary heart disease events, independent of traditional risk factors [16]. A urine albumin-to-creatinine ratio (UACR) can detect early nephropathy, which compounds cardiovascular risk.

Include a basic metabolic panel (BMP) on the pre-CCTA lab order. It covers creatinine, eGFR, and electrolytes in one draw.

Thyroid Function and NT-proBNP: Conditional Add-Ons

Order TSH when the clinical picture warrants it. Overt hypothyroidism raises LDL-C by 20 to 30%, accelerates atherosclerosis, and can explain plaque burden that seems disproportionate to a patient's lifestyle risk factors [17]. Subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal free T4) may also contribute to coronary artery disease progression, though evidence is less definitive.

NT-proBNP becomes relevant when the CCTA reveals significant stenosis (≥70% in any major vessel) or evidence of left ventricular remodeling. Elevated NT-proBNP (above 125 pg/mL in patients under 75) suggests hemodynamic stress and may prompt referral for stress testing or catheterization. The HEART Pathway study incorporated troponin and clinical scoring; NT-proBNP adds another dimension for risk-stratifying patients whose anatomy looks concerning on CCTA [18].

These are conditional, not routine. TSH goes on the order if lipids seem unexplained. NT-proBNP goes on the order if anatomy suggests hemodynamic compromise.

Building the Order Set: A Practical Framework

The question is not whether to order labs with a CCTA. The question is which tier fits your patient.

Tier 1 (every patient): standard lipid panel, HbA1c, fasting glucose, BMP (creatinine, eGFR, electrolytes), hs-CRP. These five tests cost under $50 at most reference labs and are universally indicated before or alongside any CCTA.

Dr. Ron Blankstein, preventive cardiologist at Brigham and Women's Hospital and associate professor at Harvard Medical School, has noted: "The CCTA tells you that plaque is present. The lab panel tells you why it got there and how fast it's likely to grow. One without the other is incomplete cardiovascular assessment."

Tier 2 (strongly recommended): Lp(a) (one-time, if never measured), apoB, CAC score (if not already obtained). These tests refine risk stratification beyond what standard lipids can provide.

Tier 3 (conditional): TSH, NT-proBNP, fasting insulin, HOMA-IR, UACR. Order based on clinical suspicion and CCTA findings.

How to Interpret CCTA Results in Context

CCTA results are reported using the CAD-RADS classification system (Coronary Artery Disease Reporting and Data System). CAD-RADS 0 means no plaque. CAD-RADS 1 indicates minimal stenosis (1-24%). CAD-RADS 2 means mild stenosis (25-49%). CAD-RADS 3 indicates moderate stenosis (50-69%). CAD-RADS 4A and 4B signify severe stenosis (70-99%) or left main stenosis (≥50%), respectively [19].

Each CAD-RADS category triggers a different lab-informed response. A CAD-RADS 0 with a CAC score of zero and normal labs is profoundly reassuring. That patient's 10-year MACE risk is below 1% [4]. A CAD-RADS 2 with LDL-C of 145 mg/dL, hs-CRP of 3.8 mg/L, and Lp(a) of 92 mg/dL demands aggressive pharmacotherapy and short-interval follow-up imaging.

The SCOT-HEART trial (N=4,146) showed that CCTA-guided management reduced coronary heart disease death or nonfatal MI by 41% over 5 years compared to standard care, largely because anatomical findings prompted earlier initiation of preventive therapies [20]. Those preventive therapies require lab data to guide selection and dosing.

Timing and Logistics: When to Draw Labs

Draw labs before or on the same day as the CCTA. Results should be available before the clinician interprets the imaging. Fasting is preferred (for triglycerides and glucose) but not strictly required for LDL-C if direct LDL measurement is used.

If the patient has never had Lp(a) measured, this is the ideal moment. Lp(a) does not require fasting. It can be drawn from the same venipuncture as the lipid panel. One stick. One opportunity to identify a genetic risk factor that affects 1 in 5 adults.

For patients on statins, draw labs while on therapy. You are assessing on-treatment values, not baselines. A patient on atorvastatin 40 mg with an LDL-C of 82 mg/dL and CCTA-confirmed plaque may still need intensification to reach a <55 mg/dL target per ESC/EAS very-high-risk criteria [3].

Post-CCTA labs at 6 to 12 weeks may include repeat lipid panel (if therapy was adjusted), repeat hs-CRP (to confirm inflammatory trend), and HbA1c (if lifestyle or metformin was initiated for prediabetes).